Holen Sie sich die Stockscreener-App
14.10
1.05%
-0.15
Handel nachbörslich:
14.10
Schlusskurs vom Vortag:
$14.25
Offen:
$13.8
24-Stunden-Volumen:
674.53K
Relative Volume:
0.57
Marktkapitalisierung:
$1.23B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-106.81M
KGV:
-4.2576
EPS:
-3.3117
Netto-Cashflow:
$-8.40M
1W Leistung:
+2.03%
1M Leistung:
+53.09%
6M Leistung:
+91.84%
1J Leistung:
+16.05%
1-Tages-Spanne:
$13.53
$14.32
1-Wochen-Bereich:
$13.49
$14.78
52-Wochen-Spanne:
$5.1501
$15.12
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Vergleichen Sie IMNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
14.10 | 1.24B | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Eingeleitet | Goldman | Buy |
| 2025-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2025-04-02 | Eingeleitet | Lake Street | Buy |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
Can machine learning forecast Immunome Inc. recoveryJuly 2025 Summary & Risk Managed Investment Signals - newser.com
Reversal indicators forming on Immunome Inc. stockTrade Analysis Report & Real-Time Volume Surge Alerts - newser.com
How to build a custom watchlist for Immunome Inc.July 2025 Reactions & Safe Capital Growth Plans - newser.com
Using fundamentals and technicals on Immunome Inc.Weekly Trading Summary & Community Driven Trade Alerts - newser.com
Is it too late to sell Immunome Inc.July 2025 Update & High Yield Stock Recommendations - newser.com
How Immunome Inc. stock reacts to global recession fearsMarket Rally & Risk Managed Investment Strategies - newser.com
How moving averages guide Immunome Inc. tradingJuly 2025 Opening Moves & Consistent Income Trade Ideas - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Immunome (NASDAQ:IMNM) - MarketBeat
Is Immunome Inc. reversing from oversold territory2025 AllTime Highs & Technical Confirmation Alerts - newser.com
Immunome, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Immunome, Inc. Hits Day High with 16.4% Surge in Stock Price - Markets Mojo
Immunome (NASDAQ:IMNM) Trading Up 11.5%What's Next? - MarketBeat
Immunome, Inc. Hits Day High with Strong 7.93% Intraday Surge - Markets Mojo
Can trapped investors hope for a rebound in Immunome Inc.Short Setup & Capital Efficient Trade Techniques - newser.com
Key resistance and support levels for Immunome Inc.2025 Earnings Impact & Precise Swing Trade Alerts - newser.com
Wealth Enhancement Advisory Services LLC Purchases 1,643 Shares of Immunome, Inc. $IMNM - Defense World
How high can Immunome Inc. stock go2025 Dividend Review & Short-Term High Return Ideas - newser.com
Trend analysis for Immunome Inc. this weekMarket Risk Analysis & Growth Oriented Trade Recommendations - newser.com
Immunome Inc. stock chart pattern explainedIndex Update & Weekly Breakout Stock Alerts - newser.com
Assessing Immunome (IMNM) Valuation Following New Target Discovery Partnership with Infinimmune - Sahm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635c4 - MarketScreener
Does Immunome Inc. fit your quant trading modelPortfolio Update Report & Verified Momentum Stock Alerts - newser.com
Market reaction to Immunome Inc.’s recent newsJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 - BioSpace
Signal strength of Immunome Inc. stock in tech scanners2025 Trade Ideas & Weekly Momentum Picks - newser.com
Published on: 2025-10-03 01:11:18 - newser.com
Immunome, Inc. Hits Day High with Strong 8.09% Intraday Surge - Markets Mojo
How Market Conditions Affect Ginni Filaments Limiteds Growth StrategyCash Flow Trends & We Spotted the Next Tesla – See Inside - earlytimes.in
Is Immunome Inc a good long term investmentEconomic Indicators Overview & Access Powerful Market Insights - earlytimes.in
Voya Investment Management LLC Has $127,000 Stock Holdings in Immunome, Inc. $IMNM - Defense World
Immunome, Inc. Hits Day High with 14.13% Surge in Stock Price - Markets Mojo
Immunome, Inc. Hits Day High with 15.31% Surge in Stock Price - Markets Mojo
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunome Inc-Aktie (IMNM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
| SIEGALL CLAY B | President and CEO |
Nov 21 '24 |
Buy |
9.54 |
66,057 |
630,263 |
485,693 |
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):